P2P Call Guide

How to Win a P2P Call for Biologic Therapy (Autoimmune) Denied by MA Plans

Payer-specific strategy, medical necessity arguments, and the exact phrases to use when Medicare Advantage denies Biologic Therapy (Autoimmune) (CPT J0135, J1745, J0717).

Why MA Plans Denies Biologic Therapy (Autoimmune)

Step therapy not completed (conventional DMARDs first)

Prior biologic trial not documented

Biosimilar required before brand-name biologic

Know Medicare Advantage's Criteria

Medicare Advantage plans must cover all services covered by Original Medicare (CMS NCDs and LCDs) but may require prior auth. Plans use various criteria including InterQual, MCG, and proprietary guidelines.

Key policies to know:

  • Must cover all services covered by Original Medicare
  • Can require prior authorization not required by Original Medicare
  • CMS NCDs and LCDs serve as coverage floor
  • Organization determinations must be issued within 14 days (72 hours for expedited)

MA Plans's Specific Approach to Biologic Therapy (Autoimmune)

Applicable Policy

CMS does not have specific NCDs for most biologics -- covered under Part B (infused) or Part D (self-injected)

How MA Plans Typically Denies This

MA plans apply their own formulary for Part D biologics and may have different step therapy than commercial plans. Part B biologics (infused) are generally covered if medically necessary but MA plans may require prior auth.

Your Strategy for This Payer

For Part B biologics, emphasize that coverage follows Medicare guidelines. For Part D, you're subject to the plan's formulary. File a coverage determination request and cite the Part D regulations requiring exceptions when formulary drugs are not appropriate.

Key Phrase to Use on the Call

"This biologic is medically necessary and meets Medicare coverage criteria. The patient has documented failure of formulary alternatives, supporting a coverage exception under the Part D exception process."

Building Your Medical Necessity Argument

Document failure, intolerance, or contraindication to step therapy agents

Note disease activity scores (DAS28, CDAI, PASI)

If biosimilar switch requested, document clinical reason for brand

Reference comorbidities that limit alternative treatments

P2P Call Tips for MA Plans

Cite the relevant CMS NCD or LCD -- MA plans cannot deny what Medicare covers

If the service has a CMS NCD, that trumps the MA plan's internal criteria

Reference CMS regulations on MA coverage obligations

Request expedited determination if clinical urgency exists

Guidelines to Reference

  • ACR Guidelines for Rheumatoid Arthritis Treatment
  • AGA Guidelines for Biologic Therapy in IBD
  • AAD Guidelines for Biologic Therapy in Psoriasis

Relevant CPT Codes

CPT J0135CPT J1745CPT J0717

Specialty: Rheumatology / Gastroenterology / Dermatology

Want the full strategy?

The P2P Playbook covers payer-specific approaches for Biologic Therapy (Autoimmune) denied by MA Plans -- plus 15 denial objections with word-for-word responses, what reviewers are actually thinking, and the 60-second prep framework. Written by a medical director who reviewed cases for major payers.

Get The P2P Playbook -- $39

Get a personalized P2P script in 60 seconds

Enter your specific case details and our AI generates a structured prep script tailored to MA Plans's criteria.

More Biologic Therapy (Autoimmune) P2P Guides

More MA Plans P2P Guides